In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

The author has completed the ICMJE form and declares the following conflicts of interest: She is a research assistant and principal investigator at a fetal medicine centre involved in the nipocalimab ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The ...

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational ...

Johnson & Johnson (NYSE:JNJ), a global healthcare leader, finds itself at a pivotal juncture as it navigates a landscape of promising pipeline developments, strategic acquisitions, and looming ...

The company recently announced positive Phase 3 data for nipocalimab in patients with generalized myasthenia gravis (gMG). JNJ projects peak sales potential of over $5 billion for nipocalimab ...